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Introduction
Stage III unresectable non-small cell lung cancer (NSCLC) 
represents approximately 20% (1) of all patients diagnosed 
with NSCLC. For years, the standard treatment has been 
thoracic radiotherapy 60–66 Gy in 30–33 daily fractions 
with concomitant cisplatin based chemotherapy (2), offering 
an overall survival rate at 5 years between 15–25% (3). 
Nowadays, consolidation with Durvalumab represents 
the new standard of care in patients with PD-L1 ≥1% 
and no progression after chemoradiation (4). However, 
intrathoracic progression in the Durvalumab arm showed 
just a little difference with the placebo arm, 36.6% vs. 
48.1%. Therefore in stage III clinical scenario, local relapse 
continues being a mayor challenge. 
Specifically, local relapse in stage III NSCLC can vary 
from 20% to 50% (5). Dose escalation with conventional 
radiotherapy to the lung tumor is related to higher 
local control but also to a higher toxicity. In that sense, 
the RTOG 0617 (6) study was a game-changer, as it 
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demonstrated how, higher doses to organs at risk like the 
heart, were fundamental to explain the toxicity seen at dose 
escalation studies. 
On the other hand, stereotactic body radiotherapy 
(SBRT) encompasses a technique that can deliver high dose 
conformal radiation through multiple radiation beams with 
steep dose gradients in 3–8 fractions. In early stage NSCLC, 
SBRT studies have demonstrated local control rates as far 
as 94% 3 years post-treatment (7,8). Nevertheless, in very 
central lesions or tumors with mediastinal lymph node 
infiltration, grade 3 or higher toxicity can reach 46% (9).
Consequently, using dose escalation with SBRT 
technique to improve local control in stage III NSCLC 
seems an attractive strategy. Scientific literature available 
on the topic as far as dose to deliver, toxicity profile and 
possible concomitant treatments to combine is scarce. This 
systematic review summarizes the current scientific evidence 
on the use of SBRT in locally advanced inoperable NSCLC 
(stage III). 
Material and methods
A systematic review on the literature was performed using 
PubMed-Medline, Embase and Scopus databases. Relevant 
articles on SBRT usage in inoperable stage III NSCLC 
were identified using the following terms in the Medical 
Subject Heading (MeSH): 
(SBRT or SABR or stereotactic [MeSH Terms]) AND 
(NSCLC or Carcinoma or Non small cell lung or Non-
small-cell Lung or Lung carcinoma or Non-small-cell Lung 
Carcinoma or Nonsmall Cell lung Carcinoma or Nonsmall 
Cell Lung Cancer or Non-Small-Cell Lung Carcinoma or 
Non Small Cell Lung Carcinoma or Non-Small Cell Lung 
Cancer [MeSH Terms]) AND (Stage III [MeSH Terms]. 
Search syntax was adapted to Embase and Scopus 
databases in order to find relevant articles on the topic. We 
included studies up to December 2019.
The articles found on the systematic review were 
independently examined by two investigators (OLA and 
ANM). Interesting articles related to the topic that were 
found outside the initial systematic review were included. 
Discrepancies between the reviewers were analyzed together 
and a consensus was reached. 
Included studies for the review were those that 
administered SBRT as a boost after or before conventional 
chemoradiotherapy, those that administered SBRT in 
monotherapy and reviews on the administration of SBRT 
in inoperable stage III NSCLC. Studies that did not report 
administered doses or that did not include outcomes such 
as toxicity, progression free survival or local control were 
excluded. Articles that were not published in English or did 
not have the complete text available were also excluded. 
This systematic review has been carried out following 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines (Figure 1). To measure 
quality of the studies the NIH quality-measure tool for this 
purpose was used available at https://www.nhlbi.nih.gov/
health-topics/study-quality-assessment-tools.
Results
Systematic review on the three databases above mentioned 
extracted 141 studies, 11 of which met inclusion criteria 
(5,10-19) (Figure 1). Two studies were reviews (5,15), 
one did not include clinical data (17), two studies had 
preliminary results (11,12), 3 were prospective studies 
and another 3 were retrospective. For quantitative and 
qualitative analysis 6 articles were fully reviewed (Table 1). 
In the studies that met the inclusion criteria, a total of 134 
patients affected of stage III inoperable NSCLC were treated 
with SBRT some time during the therapeutic strategy. These 
studies were carried out between 2008 and 2019 in different 
centers, majority of them in United States, and one in China. 
In relation to the design of the studies included, 3 studies had 
a prospective design, 2 of which were phase I. The remaining 
3 were retrospective series. Sample size for each study and 
results are described in Table 1. 
Out of the 6 original studies that considered SBRT 
administration in stage III NSCLC, 1 employed SBRT in 
monotherapy (10) and the other 5 employed SBRT as a 
dose escalation technique in the context of conventional 
chemoradiotherapy (13,14,16,18,19). 
Studies that administered SBRT as a dose intensification 
technique had a median dose in the conventional 
radiotherapy of 50.4 Gy in a median of 28 fractions. 
Additionally, the median dose in the SBRT boost was 22.25 
Gy delivered in 2 to 7 fractions. 
Systemic treatment employed for conventional 
chemoradiotherapy was platinum-based. One of the 
studies included FDG PET-CT scan as a tool for 
contouring the gross tumor volume (GTV) for the boost. 
The rest of the studies relied on CT scans to delineate 
the GTV. Three studies included the primary tumor 
and the affected lymph nodes in the SBRT therapeutic 
volume. The remaining two, on the contrary, included 
the primary tumor but not the lymph nodes. Reported 
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median follow-up was 18.75 months. Median local control 
was 76%. As far as toxicity is concerned, 12% of patients 
experienced grade 3 or higher toxicity. 
The phase I dose-escalation study by Hepel et al. included 
12 patients (13). Primary objective was to obtain dose 
limiting toxicity (DLT) for toxicity such as pneumonitis, 
oesophageal fistula, cardiac toxicity, bone fractures or 
dermatitis. Four dose schedules are described, from 16 to 
28 Gy administered in 2 fractions and incrementing dose 
per fraction by 4 Gy in each cohort. Following its primary 
objective (DLT), 3 patients per cohort-dose were included 
using a classical 3×3 trial design. 
Patients on Hepel’s study underwent chemoradiotherapy 
previously at a dose of 50.4 Gy in 28 fractions. Most 
common systemic treatment to combine with radiation 
was 2 cycles of cisplatin and etoposide every 3 weeks or 
carboplatin-taxol weekly for 6 weeks. After conventional 
chemoradiotherapy, a CT scan was obtained to address the 
remaining tumor in order to plan SBRT treatment that 
would be administered 1 to 4 weeks after. 
In this case, both the remaining primary tumor and 
lymph nodes were included in the treatment field. Four 
dose cohorts were reached, where grade 3 or superior 
toxicity was not observed. 42% of the patients received 
consolidation chemotherapy for 2 more cycles. 
With a median follow-up of 15.5 months, local control 
the first year was 78% and 100% in 6 patients who received 
24 Gy or higher doses. Overall survival of the whole study 
was 67%. One patient on the 24 Gy cohort experienced 
grade 5 toxicity in peribronchial vasculature. 
The other phase I dose-escalation study published in 2017 
by Higgins et al. (14) included 19 patients and its primary 
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objective was also to determine the maximal tolerated dose 
(MTD). Four dose cohorts were designed: 18 Gy (9 Gy 
× 2 Fr), 20 Gy (10 Gy × 2 Fr), 30 Gy (6 Gy × 5 Fr) and 
35 Gy (7 Gy × 5 Fr). In a similar manner, 3 patients 
per dose-cohort were included. They all underwent 
conventional chemoradiotherapy previously at a dose of 
44 Gy in 2 Gy fractions concurrent to weekly carboplatin 
(45–50 mg/m2) and paclitaxel (AUC 2).
Consolidation chemotherapy was at the discretion of the 
clinician and 73% received it. The third dose cohort (6 Gy 
× 5 Fr) had a grade 5 tracheo-esophageal fistula that derived 
in death of the patient. Another 2 patients at the fourth dose 
cohort (7 Gy × 5 Fr) presented grade 3 or higher toxicity: 
one grade 5 hemoptysis and one grade 3 hypoxia. With 
these findings, authors conclude that the save dose range 
would be 20 Gy in 2 fractions.
Residual disease in this case was measured with CT scans 
and SBRT was delivered to the primary tumor and the 
remaining lymph nodes. Local control rate was 59% the 
first year and overall survival was 39%.
The third and last prospective study was published in 
2017 by Kumar et al. (16). Patients with inoperable stage IIB 
(4p) and IIIA‒B (38p) were included. Median follow-up was 
25 months. Primary objective of the study was to determine 
the safety or toxicity profile of an SBRT boost. All patients 
received conventional chemoradiotherapy (59.4–60 Gy with 
standard 180–200 cGy fractions). In this case, PET-CT was 
achieved 1 month after termination of chemoradiotherapy, 
and the remaining disease was included in the SBRT 
boost. 2 dose cohort were designed: 10 Gy × 2 fractions for 
tumors in the periphery (28p) and 6.5 Gy × 3 fractions for 
central tumors (14p). Boost did not include lymph nodes. 
The median time between chemoradiotherapy and SBRT 
delivery was 2.9 months. One-year local control of the study 
was 63.6%. Toxicity rate was 11.9% grade 3 with no grade 4 
or higher toxicity. 
Out of the three retrospective studies that met the 
selection criteria, the study by Cong stands out due to its 
innovative therapeutic approach (10). In this case, SBRT 
is administered in monotherapy for stage III NSCLC with 
a Cyberknife at a median dose of 35 Gy in 5 fractions. 
Primary tumor and lymph nodes were both included in the 
treatment volume. Median follow-up time was 17 months 
with a local control rate of 61%. Grade 3 toxicity or higher 
was 9.8%. 
As far as the retrospective work of Salazar et al. (18), 
SBRT was delivered in different NSCLC clinical scenarios, 
including metastasis. In summary, 30 patients were stage 
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III and were included in this review. They received 
conventional radiotherapy total dose 45 Gy in 25 fractions 
and SBRT boost in 3 fractions of 7.5 Gy each to the 
primary tumor (excluding lymph nodes). Obtained local 
control by stages was: 73% in stage IIIA and 47% in stage 
IIIB. Information about systemic therapy was not available. 
No grade 3 or higher toxicity was detected. 
Finally, the retrospective study by Karam et al. (19) 
included 16 patients ,  a l l  s tage III .  Conventional 
chemoradiotherapy was delivered with a median total 
dose of 50.4 Gy. In order to identify the SBRT volume 
during treatment, 4 fiducial markers were placed prior to 
simulation. Median follow-up reached 14 months, with an 
overall survival at 1 year of 78%. Local and regional control 
were 76% and 79% respectively. Toxicity was not graded 
accurately, although information on one patient developing 
hemoptysis and another pneumonitis is given. 
The overall quality of the studies was measured using the 
NIH “Study quality assessment tools”. Specifically, “before-
after studies with no control group” was used to measure the 
prospective studies, and the “quality case series studies” was 
used to measure the retrospective studies (see Figures 2,3). 
Discussion
Standard treatment for stage III inoperable NSCLC 
remains conventional chemoradiotherapy; systemic therapy 
being platinum-based and radiation doses going up to 60–
66 Gy in 2 Gy daily fractions (4,20). 
The primary objective of this systematic review was to 
stablish first clinical experiences and the existing scientific 
evidence supporting the use of SBRT in inoperable stage 
III NSLCL as a tool to decrease local failure. Six relevant 
studies were found. After careful examination, two principal 
therapeutic strategies were identified: on one hand, the use 
of SBRT as a boost after conventional chemoradiation, and 
on the other, the use of SBRT in monotherapy in those 
patients that are not good candidates for conventional 
chemoradiation. 
Interestingly, SBRT treatment volume design differs 
from study to study. Sometimes it includes just the primary 
tumor in order to reduce toxicity, and in other cases, it 
Figure 2 Study Quality assessment tool for before-after studies with no control group. 
 Yes;  No.
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includes positive lymph nodes too instead. 
SBRT volume
Stage III NSCLC disease is characterized by lymph node 
involvement in the mediastinum. The administration of 
SBRT in this stage poses an important risk of toxicity due 
to proximity of critical organs like bronchi, esophagus, 
large vessels and the heart. Classically, central lung lesions 
have been defined as those at a distance of 2 cm or less 
from the mediastinum or principal bronchi (21). In studies 
that used SBRT to central lesions in early stages, grade 3 
or higher toxicity was reported as 9% (22). Nevertheless, 
treatment volumes did not include positive lymph nodes. 
Up to date, SBRT administration to treat lymph nodes has 
been anecdotic and doses to administer are therefore not 
clear (23).
In our systematic review, 5 out of 7 studies used SBRT 
technique as a dose-intensification method after concurrent 
chemoradiotherapy. In these studies, initial disease-volume 
is reduced with conventional treatment in order to pursue 
a safer SBRT treatment volume. Two studies (Salazar 
and Kumar et al.) include solely the primary tumor in the 
intention to treat volume. Grade 3 toxicity reported by 
these authors is 0% and 11.9% respectively. Remaining 
studies include the involved lymph nodes in the SBRT 
volume as well as the primary tumor and grade 3 toxicity 
reported varies from 8% to 20%.
Imaging technique to determine the GTV
Choice of imaging technique in the design of the GTV 
differs from study to study. Residual disease identification 
after conventional chemoradiotherapy is fundamental to 
make an impact in locoregional control and most probably, 
on overall survival. In this regard, just one study (16) 
inc luded  PET-CT at  one-month  comple t ion  o f 
chemoradiotherapy to determine the residual disease. 
At present, the standardization of radiomics in PET 
scans and the study of its prognostic value for lung cancer 
has been studied (24). Whether PET can be an independent 
prognosis factor in lung cancer in order to select patients 
for treatment intensification after chemoradiation is also 
currently under consideration (25). 
Dose election
In the studies previously mentioned, median dose for 
SBRT was 22.25 Gy with a number of fractions ranging 
from 2 to 7. Two studies are phase I dose-escalation 
Figure 3 Quality assessment tool for case series studies. 
 Yes;  No. NA, not available. 
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studies. Higgins (14) reported an MTD at 6 Gy × 5 Fr dose 
after conventional chemoradiation of 44 Gy 2 Gy/fraction. 
Authors conclude that 20 Gy in 2 fractions of 10 Gy is safer. 
Nevertheless, in the other phase I study by Hepel (13), 
local control is higher when dose is equal o higher than 
24 Gy in 2 fractions, and in contrast, toxicity is lower (8% 
versus 15.78%). The gain in local control in the Hepel 
study (78% vs. 59%) could be related to the biological 
effective dose administered (BED), which is superior: 126.7 
versus 112.3 Gy.
On the other hand, locoregional control is not specified 
in the different dose cohorts, so concluding which dose per 
fraction is best for this objective is difficult. In this regard, 
Kumar et al. (16) concluded that local and regional control 
are similar in the different schemes evaluated: 10 Gy × 2 
Fr vs. 6.5 Gy × 3 Fr. However, data in this study has given 
us much thought. To start, local failure in the 6.5 Gy × 3 
cohort and 10 Gy × 2 cohort is 14% and 21% respectively. 
Meanwhile, biological effective dose for each cohort goes as 
follows: BED10 32.2 versus 40 Gy. In conclusion, the higher 
BED cohort has a worse local failure, the opposite of what 
is generally accepted. To our understanding, this may be in 
relation to the immune changes occurring after repeated 
doses of radiation, favoring the 6.5 Gy × 3 cohort as seen 
in mice studies on the topic (26). In addition, ablative 
doses per fraction of around 10 Gy, have a deleterious 
effect on interferon activation genes due to the activation 
of exonuclease TREX1, who is capable of fragmenting 
the tumor nucleic acid in the dendritic cell and as a result, 
inhibit cGAS-STING pathway (27,28).
Consolidation after SBRT
In the studies selected, there is a lack of information 
regarding the use of consolidation systemic therapy. Out 
of the three studies that do inform on the matter, the 
proportion of patient receiving this treatment varies from 
6% to 73%. In the present, consolidation treatment with 
immunotherapy is standard of care due to the publication 
of  the PACIFIC TRIAL (29) ,  where durvalumab 
demonstrated an improved overall survival: 83.1% at 1 year. 
If we compare OS of SBRT studies and OS of the 
PACIFIC trial, it is clear that the second is higher. In 
terms of intrathoracic disease control, the combination 
of conventional chemoradiotherapy and immunotherapy 
manages a 60% local control. Whether the combination of 
triple therapy (conventional chemoradiotherapy + SBRT + 
durvalumab) is safe or effective is yet to be determined in 
future studies. Nevertheless, the combination of multisite 
SBRT and pembrolizumab has already been tested and 
toxicity was much lower than expected (30). 
As previously explained, according to research on 
fractionation and cGAS-STING pathway activation, a 
systemic immune response with SBRT can be obtained 
at lower radiation doses, and therefore toxicity to the 
mediastinum organs could be avoided. In addition, the 
smaller treatment fields achieved with SBRT technique 
decrease  surrounding lymphopenia  compared to 
conventional radiation and overall make this technique 
safer and more suitable for immune activation and immune 
combinations. 
Toxicity
Toxicity observed throughout the studies is diverse and does 
not follow a linear relation to dose in most cases. Majority 
of studies applied dose constraints published previously by 
other authors that administered lung SBRT. In some cases, 
like the deceased due to hemoptysis in the Hepel study (13), 
maximum tolerated doses to the proximal bronchial tree 
were not stablished. As a result, an amendment was made 
for treatment of future patients stablishing a new dose 
constraint to this organ at risk. Other authors (16), adapted 
fractionation in central lesions to be more conservative. 
None of the studies report acute irreversible toxicity, 
although distinction between acute and chronic toxicity 
is not clear. Higgins group (14) considers acute toxicity 
whatever is detected in the first 30 days post-SBRT delivery 
and other groups stablish acute toxicity in the first 90 days. 
In any case, severe toxicity appears late, for which dose-
escalation studies are not adequate. 
In the RTOG 0813 study (31), where SBRT was 
delivered to central tumors, a time-to-event continual 
reassessment method (TITE-CRM) (32) design was used 
that account for this late toxicity. The advantage of this 
method is it has the ability to calculate MTD without 
exposing the patient to a higher toxicity. 
Out of all the studies in this review that evaluated 
toxicity, 5 patients presented with grade 5 toxicity and 19 
with grade 3 toxicity. The majority of grade 5 toxicities were 
related to hemoptysis, fistulas or excess dose to proximal 
bronchial tree and its vasculature. 
Quality of the studies
The overall quality of the studies was measured with 
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the NIH tool that was more adequate for each design. 
Prospective studies were analyzed with the “before-after 
studies with no control group” (Figure 2) and retrospective 
studies were analyzed with the “Case Series Studies Tool” 
(Figure 3). Out of the retrospective studies selected, one 
study did not have the statistics clearly outlined, another 
study did not include grades on toxicity, and all 3 studies 
included heterogeneous population with different disease 
stages. Only one of the studies specified clearly the patient 
characteristics. The nature of SBRT treatment on the 
other hand, did not allow for double blinded design in 
the prospective studies and the scarce number of patients 
treated with SBRT does not permit to draw conclusions on 
the heterogeneous stage III NSCLC population. 
Future perspectives
At present, SBRT administration in stage III is being studied 
in 7 different clinical trials (Table 2). One of them combines 
SBRT with TKI (NCT03727867). Six phase II studies 
are ongoing, of which one has already closed recruitment 
(NCT01656460). One of these trials (NCT03589547) uses 
SBRT and Durvalumab as a neoadjuvant strategy before 
definitive chemoradiation.
Conclusions
Current evidence to administer SBRT in inoperable stage 
III locally advanced NSCLC is based on two phase I trials. 
As far as fractionation is concerned, authors establish that 
2 fractions of 10 or 12 Gy each are safe after conventional 
chemoradiation and obtain a local control of around 
78%. Hence, increasing biological effective dose above 
112.3 Gy seems to have a better local control compared to 
conventional radiation. Ongoing phase II and III clinical 
trials will determine the efficacy of this treatment approach 




Table 2 Ongoing clinical trials found in clinicaltrial.org on Feb 2020 with the keywords “SBRT stage III NSCLC”
Clinical trial 
identifier







Recruiting 25 II 60/30 20/2 Fr Not available




70 II 66/33 LN 54/3 Fr T Not available
NCT01656460 CRT  SBRT Completed 12 II 50.4/28 16/2 Fr; 
20/2; 24/2; 
28/2 
1 G5 hemoptysis; 
in Arm 3; 1 G4 late 
dyspnea in Arm 4
NCT01933568
N12HYB
CRT + SBRT for 
peripheral T <5 
cm
Completed 15 I CRT to LN and SBRT to PT 
concurrent to cisplatin
Not available
NCT01345851 CRT  SBRT Active, not 
recruiting






5 Fr boost Not available
NCT01657617 SBRT  CRT Completed 35 II CRT 19.5/3 Fr CT; 
20/2 PT
2 G5 hemoptysis; 2 
G3 pneumonitis
NCT02262325 SBRT  CRT Recruiting 34 II 30 Fr 2 Fr Not available




300 III NA 60/8 Fr CT;
50/5 PT
Not available
CRT, conventional chemoradiation; SBRT, stereotactic body radiotherapy; Fr, fractionation in total Gy and number of fractions; LN, lymph 
nodes; T, tumor; NI, no information; PT, peripheral tumors; CT, central tumors; TKI, tyrosine kinase inhibitor; NA, not applicable.
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